Mein Warenkorb

Human LILRB4 / CD85k / ILT3 Protein, His Tag, low endotoxin (MALS verified)

User Reviews
Product Number/Spec
Price
Menge
LI4-H52H7-100ug
$395.00
LI4-H52H7-1mg
$2875.00
ETA of in-stock products:2 business days
Gesamtanzahl Product Amount$ 0

Product Details

  • Synonyms

    LILRB4, ILT3, LIR5, CD85K, HM18

  • Source

    Human LILRB4, His Tag (LI4-H52H7) is expressed from human 293 cells (HEK293).

    Predicted N-terminus: Gln 22

    Request for sequence
  • Molecular Characterization

    LILRB4 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 28.2 kDa. The protein migrates as 32-43 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Kunden haben auch angesehen

Data Display

  • SDS-PAGE

    LILRB4 SDS-PAGE

    Human LILRB4, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    LILRB4 SEC-MALS

    The purity of Human LILRB4, His Tag (Cat. No. LI4-H52H7) is more than 95% and the molecular weight of this protein is around 28-41 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     LILRB4 ELISA

    Immobilized Human LILRB4, His Tag (Cat. No. LI4-H52H7) at 1 μg/mL (100 μL/well) can bind Anti-LILRB4 Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     LILRB4 SPR

    Human ANGPTL7, His Tag immobilized on CM5 Chip can bind Human LILRB4, His Tag (Cat. No. LI4-H52H7) with an affinity constant of 4.67 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

    Protocol

User Reviews
Publish Comment

Background Introduction

Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

Frontier Progress

 
Drug Development Progress
  • English Name:

    Leukocyte immunoglobulin-like receptor subfamily B member 4

  • Category:

  • Listed Drugs Count:

    0 Details

  • Clinical Drugs Count:

    7 Details

  • Highest R&D Stage:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Kunden haben auch angesehen
  • Data Display
  • User Reviews
  • Hintergrund
Kontaktieren Sie uns